5-fluorouracil and oxaliplatin with or without docetaxel in the first-line treatment of HER2 negative locally advanced (LA) unresectable or metastatic gastric or gastro-esophageal junction (GEJ) adenocarcinoma (GASTFOX-PRODIGE 51): A randomized phase III trial sponsored by the FFCD

ANNÉE

2023

AUTEURS

Zaanan A, Bouche O, de la Fouchardiere C, Samalin-Scalzi E, Le Malicot K, Pernot S, Artru P, Ly Lebrun Aldabbagh K, Khemissa Akouz F, Castanie H, Laly M, Botsen D, Muller M, Roth G, Lecomte T, Phelip JM, Lepage C, Louvet C

CONGRÈS/REVUE

ESMO

LIEN PUBLICATIONS ASSOCIÉES